nodes	percent_of_prediction	percent_of_DWPC	metapath
Irinotecan—TOP1—systemic scleroderma	0.436	1	CbGaD
Irinotecan—CES2—Mycophenolate mofetil—systemic scleroderma	0.125	0.28	CbGbCtD
Irinotecan—UGT1A9—Mycophenolic acid—systemic scleroderma	0.0472	0.106	CbGbCtD
Irinotecan—CES1—Mycophenolate mofetil—systemic scleroderma	0.0434	0.0974	CbGbCtD
Irinotecan—UGT1A1—Mycophenolic acid—systemic scleroderma	0.0386	0.0865	CbGbCtD
Irinotecan—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.0264	0.0591	CbGbCtD
Irinotecan—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.0216	0.0483	CbGbCtD
Irinotecan—ABCG2—Leflunomide—systemic scleroderma	0.0192	0.043	CbGbCtD
Irinotecan—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.0149	0.0335	CbGbCtD
Irinotecan—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0131	0.0294	CbGbCtD
Irinotecan—ABCG2—Mycophenolate mofetil—systemic scleroderma	0.0119	0.0266	CbGbCtD
Irinotecan—ALB—Captopril—systemic scleroderma	0.0104	0.0233	CbGbCtD
Irinotecan—ALB—Mycophenolate mofetil—systemic scleroderma	0.00817	0.0183	CbGbCtD
Irinotecan—ABCB1—Lisinopril—systemic scleroderma	0.00725	0.0163	CbGbCtD
Irinotecan—ABCC1—Methotrexate—systemic scleroderma	0.0071	0.0159	CbGbCtD
Irinotecan—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.00657	0.0147	CbGbCtD
Irinotecan—ALB—Prednisone—systemic scleroderma	0.00653	0.0147	CbGbCtD
Irinotecan—SLCO1B1—Methotrexate—systemic scleroderma	0.00599	0.0134	CbGbCtD
Irinotecan—ABCB1—Captopril—systemic scleroderma	0.00543	0.0122	CbGbCtD
Irinotecan—ABCC2—Methotrexate—systemic scleroderma	0.00526	0.0118	CbGbCtD
Irinotecan—Topotecan—TOP1—systemic scleroderma	0.00486	1	CrCbGaD
Irinotecan—ABCG2—Methotrexate—systemic scleroderma	0.00475	0.0107	CbGbCtD
Irinotecan—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.00427	0.00959	CbGbCtD
Irinotecan—ABCB1—Prednisone—systemic scleroderma	0.00342	0.00766	CbGbCtD
Irinotecan—ALB—Methotrexate—systemic scleroderma	0.00328	0.00735	CbGbCtD
Irinotecan—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00256	0.00574	CbGbCtD
Irinotecan—CYP3A4—Prednisone—systemic scleroderma	0.00205	0.00459	CbGbCtD
Irinotecan—ABCB1—Methotrexate—systemic scleroderma	0.00171	0.00384	CbGbCtD
Irinotecan—TOP1MT—lung—systemic scleroderma	0.000556	0.0683	CbGeAlD
Irinotecan—TOP1—smooth muscle tissue—systemic scleroderma	0.000445	0.0547	CbGeAlD
Irinotecan—CES2—smooth muscle tissue—systemic scleroderma	0.000404	0.0496	CbGeAlD
Irinotecan—CES2—skin of body—systemic scleroderma	0.000398	0.0489	CbGeAlD
Irinotecan—UGT1A9—digestive system—systemic scleroderma	0.000395	0.0486	CbGeAlD
Irinotecan—CES1—connective tissue—systemic scleroderma	0.000363	0.0446	CbGeAlD
Irinotecan—TOP1—tendon—systemic scleroderma	0.000334	0.0411	CbGeAlD
Irinotecan—CES2—digestive system—systemic scleroderma	0.000319	0.0391	CbGeAlD
Irinotecan—CES2—tendon—systemic scleroderma	0.000303	0.0373	CbGeAlD
Irinotecan—TOP1—lung—systemic scleroderma	0.000294	0.0361	CbGeAlD
Irinotecan—UGT1A1—digestive system—systemic scleroderma	0.000271	0.0333	CbGeAlD
Irinotecan—CES2—lung—systemic scleroderma	0.000266	0.0327	CbGeAlD
Irinotecan—CES1—digestive system—systemic scleroderma	0.000262	0.0322	CbGeAlD
Irinotecan—SLC22A3—connective tissue—systemic scleroderma	0.000252	0.031	CbGeAlD
Irinotecan—ACHE—tendon—systemic scleroderma	0.00025	0.0307	CbGeAlD
Irinotecan—SLC22A3—smooth muscle tissue—systemic scleroderma	0.000231	0.0283	CbGeAlD
Irinotecan—SLCO1B1—digestive system—systemic scleroderma	0.000226	0.0277	CbGeAlD
Irinotecan—CES1—lung—systemic scleroderma	0.000219	0.0269	CbGeAlD
Irinotecan—ABCC2—digestive system—systemic scleroderma	0.000171	0.021	CbGeAlD
Irinotecan—ABCB1—blood vessel—systemic scleroderma	0.000166	0.0204	CbGeAlD
Irinotecan—BCHE—smooth muscle tissue—systemic scleroderma	0.000163	0.0201	CbGeAlD
Irinotecan—ABCC2—tendon—systemic scleroderma	0.000163	0.02	CbGeAlD
Irinotecan—BCHE—skin of body—systemic scleroderma	0.000161	0.0198	CbGeAlD
Irinotecan—SLC22A3—lung—systemic scleroderma	0.000152	0.0187	CbGeAlD
Irinotecan—CYP2B6—skin of body—systemic scleroderma	0.000144	0.0177	CbGeAlD
Irinotecan—ABCC1—tendon—systemic scleroderma	0.000143	0.0176	CbGeAlD
Irinotecan—BCHE—digestive system—systemic scleroderma	0.000129	0.0158	CbGeAlD
Irinotecan—ABCC1—lung—systemic scleroderma	0.000126	0.0154	CbGeAlD
Irinotecan—CYP3A5—digestive system—systemic scleroderma	0.000116	0.0142	CbGeAlD
Irinotecan—CYP2B6—digestive system—systemic scleroderma	0.000115	0.0141	CbGeAlD
Irinotecan—BCHE—lung—systemic scleroderma	0.000108	0.0132	CbGeAlD
Irinotecan—ABCG2—lung—systemic scleroderma	0.000104	0.0128	CbGeAlD
Irinotecan—CYP3A5—lung—systemic scleroderma	9.67e-05	0.0119	CbGeAlD
Irinotecan—CYP2B6—lung—systemic scleroderma	9.61e-05	0.0118	CbGeAlD
Irinotecan—CYP3A4—digestive system—systemic scleroderma	8.69e-05	0.0107	CbGeAlD
Irinotecan—Back pain—Mycophenolate mofetil—systemic scleroderma	8.55e-05	0.000817	CcSEcCtD
Irinotecan—Dyspnoea—Leflunomide—systemic scleroderma	8.54e-05	0.000817	CcSEcCtD
Irinotecan—Hypotension—Mycophenolic acid—systemic scleroderma	8.54e-05	0.000817	CcSEcCtD
Irinotecan—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	8.5e-05	0.000812	CcSEcCtD
Irinotecan—Discomfort—Lisinopril—systemic scleroderma	8.49e-05	0.000811	CcSEcCtD
Irinotecan—Cerebrovascular accident—Methotrexate—systemic scleroderma	8.48e-05	0.000811	CcSEcCtD
Irinotecan—Dyspepsia—Leflunomide—systemic scleroderma	8.43e-05	0.000806	CcSEcCtD
Irinotecan—Pancreatitis—Prednisone—systemic scleroderma	8.43e-05	0.000806	CcSEcCtD
Irinotecan—Vomiting—Mometasone—systemic scleroderma	8.42e-05	0.000805	CcSEcCtD
Irinotecan—Sweating increased—Prednisone—systemic scleroderma	8.38e-05	0.000801	CcSEcCtD
Irinotecan—Feeling abnormal—Azathioprine—systemic scleroderma	8.36e-05	0.000799	CcSEcCtD
Irinotecan—Rash—Mometasone—systemic scleroderma	8.35e-05	0.000798	CcSEcCtD
Irinotecan—Asthenia—Captopril—systemic scleroderma	8.34e-05	0.000797	CcSEcCtD
Irinotecan—Dermatitis—Mometasone—systemic scleroderma	8.34e-05	0.000797	CcSEcCtD
Irinotecan—Decreased appetite—Leflunomide—systemic scleroderma	8.33e-05	0.000796	CcSEcCtD
Irinotecan—Osteoarthritis—Methotrexate—systemic scleroderma	8.31e-05	0.000795	CcSEcCtD
Irinotecan—Confusional state—Lisinopril—systemic scleroderma	8.3e-05	0.000794	CcSEcCtD
Irinotecan—Gastrointestinal pain—Azathioprine—systemic scleroderma	8.3e-05	0.000793	CcSEcCtD
Irinotecan—Headache—Mometasone—systemic scleroderma	8.29e-05	0.000793	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Leflunomide—systemic scleroderma	8.27e-05	0.000791	CcSEcCtD
Irinotecan—Insomnia—Mycophenolic acid—systemic scleroderma	8.27e-05	0.00079	CcSEcCtD
Irinotecan—Fatigue—Leflunomide—systemic scleroderma	8.26e-05	0.00079	CcSEcCtD
Irinotecan—Anaphylactic shock—Lisinopril—systemic scleroderma	8.23e-05	0.000787	CcSEcCtD
Irinotecan—Oedema—Lisinopril—systemic scleroderma	8.23e-05	0.000787	CcSEcCtD
Irinotecan—Paraesthesia—Mycophenolic acid—systemic scleroderma	8.21e-05	0.000785	CcSEcCtD
Irinotecan—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	8.2e-05	0.000784	CcSEcCtD
Irinotecan—Constipation—Leflunomide—systemic scleroderma	8.19e-05	0.000783	CcSEcCtD
Irinotecan—Pain—Leflunomide—systemic scleroderma	8.19e-05	0.000783	CcSEcCtD
Irinotecan—Infection—Lisinopril—systemic scleroderma	8.18e-05	0.000782	CcSEcCtD
Irinotecan—Anaemia—Mycophenolate mofetil—systemic scleroderma	8.17e-05	0.000781	CcSEcCtD
Irinotecan—Dyspnoea—Mycophenolic acid—systemic scleroderma	8.15e-05	0.000779	CcSEcCtD
Irinotecan—Somnolence—Mycophenolic acid—systemic scleroderma	8.13e-05	0.000777	CcSEcCtD
Irinotecan—Shock—Lisinopril—systemic scleroderma	8.1e-05	0.000774	CcSEcCtD
Irinotecan—Thrombocytopenia—Lisinopril—systemic scleroderma	8.06e-05	0.000771	CcSEcCtD
Irinotecan—Dyspepsia—Mycophenolic acid—systemic scleroderma	8.05e-05	0.000769	CcSEcCtD
Irinotecan—Neutropenia—Prednisone—systemic scleroderma	8.04e-05	0.000769	CcSEcCtD
Irinotecan—Abdominal pain—Azathioprine—systemic scleroderma	8.02e-05	0.000767	CcSEcCtD
Irinotecan—Body temperature increased—Azathioprine—systemic scleroderma	8.02e-05	0.000767	CcSEcCtD
Irinotecan—Malaise—Mycophenolate mofetil—systemic scleroderma	7.97e-05	0.000762	CcSEcCtD
Irinotecan—Hyperhidrosis—Lisinopril—systemic scleroderma	7.96e-05	0.000761	CcSEcCtD
Irinotecan—Diarrhoea—Captopril—systemic scleroderma	7.95e-05	0.00076	CcSEcCtD
Irinotecan—Decreased appetite—Mycophenolic acid—systemic scleroderma	7.95e-05	0.00076	CcSEcCtD
Irinotecan—Vertigo—Mycophenolate mofetil—systemic scleroderma	7.94e-05	0.000759	CcSEcCtD
Irinotecan—Syncope—Mycophenolate mofetil—systemic scleroderma	7.93e-05	0.000758	CcSEcCtD
Irinotecan—Leukopenia—Mycophenolate mofetil—systemic scleroderma	7.91e-05	0.000756	CcSEcCtD
Irinotecan—Feeling abnormal—Leflunomide—systemic scleroderma	7.9e-05	0.000755	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	7.89e-05	0.000754	CcSEcCtD
Irinotecan—Fatigue—Mycophenolic acid—systemic scleroderma	7.88e-05	0.000753	CcSEcCtD
Irinotecan—Nausea—Mometasone—systemic scleroderma	7.86e-05	0.000752	CcSEcCtD
Irinotecan—Anorexia—Lisinopril—systemic scleroderma	7.85e-05	0.00075	CcSEcCtD
Irinotecan—Gastrointestinal pain—Leflunomide—systemic scleroderma	7.84e-05	0.000749	CcSEcCtD
Irinotecan—Pain—Mycophenolic acid—systemic scleroderma	7.82e-05	0.000747	CcSEcCtD
Irinotecan—Constipation—Mycophenolic acid—systemic scleroderma	7.82e-05	0.000747	CcSEcCtD
Irinotecan—Weight decreased—Prednisone—systemic scleroderma	7.78e-05	0.000744	CcSEcCtD
Irinotecan—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	7.77e-05	0.000743	CcSEcCtD
Irinotecan—Cough—Mycophenolate mofetil—systemic scleroderma	7.71e-05	0.000737	CcSEcCtD
Irinotecan—Hypotension—Lisinopril—systemic scleroderma	7.69e-05	0.000735	CcSEcCtD
Irinotecan—Dizziness—Captopril—systemic scleroderma	7.69e-05	0.000735	CcSEcCtD
Irinotecan—Hypertension—Mycophenolate mofetil—systemic scleroderma	7.63e-05	0.000729	CcSEcCtD
Irinotecan—Body temperature increased—Leflunomide—systemic scleroderma	7.57e-05	0.000724	CcSEcCtD
Irinotecan—Abdominal pain—Leflunomide—systemic scleroderma	7.57e-05	0.000724	CcSEcCtD
Irinotecan—Acute coronary syndrome—Prednisone—systemic scleroderma	7.56e-05	0.000722	CcSEcCtD
Irinotecan—Feeling abnormal—Mycophenolic acid—systemic scleroderma	7.53e-05	0.00072	CcSEcCtD
Irinotecan—Myocardial infarction—Prednisone—systemic scleroderma	7.52e-05	0.000718	CcSEcCtD
Irinotecan—Hypersensitivity—Azathioprine—systemic scleroderma	7.48e-05	0.000715	CcSEcCtD
Irinotecan—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	7.47e-05	0.000715	CcSEcCtD
Irinotecan—Insomnia—Lisinopril—systemic scleroderma	7.45e-05	0.000712	CcSEcCtD
Irinotecan—Discomfort—Mycophenolate mofetil—systemic scleroderma	7.44e-05	0.000711	CcSEcCtD
Irinotecan—Paraesthesia—Lisinopril—systemic scleroderma	7.39e-05	0.000707	CcSEcCtD
Irinotecan—Vomiting—Captopril—systemic scleroderma	7.39e-05	0.000707	CcSEcCtD
Irinotecan—Dyspnoea—Lisinopril—systemic scleroderma	7.34e-05	0.000702	CcSEcCtD
Irinotecan—Rash—Captopril—systemic scleroderma	7.33e-05	0.000701	CcSEcCtD
Irinotecan—Dermatitis—Captopril—systemic scleroderma	7.32e-05	0.0007	CcSEcCtD
Irinotecan—Somnolence—Lisinopril—systemic scleroderma	7.32e-05	0.0007	CcSEcCtD
Irinotecan—Headache—Captopril—systemic scleroderma	7.28e-05	0.000696	CcSEcCtD
Irinotecan—Confusional state—Mycophenolate mofetil—systemic scleroderma	7.27e-05	0.000695	CcSEcCtD
Irinotecan—Dyspepsia—Lisinopril—systemic scleroderma	7.25e-05	0.000693	CcSEcCtD
Irinotecan—Abdominal pain—Mycophenolic acid—systemic scleroderma	7.23e-05	0.000691	CcSEcCtD
Irinotecan—Body temperature increased—Mycophenolic acid—systemic scleroderma	7.23e-05	0.000691	CcSEcCtD
Irinotecan—Oedema—Mycophenolate mofetil—systemic scleroderma	7.21e-05	0.00069	CcSEcCtD
Irinotecan—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	7.21e-05	0.00069	CcSEcCtD
Irinotecan—Infection—Mycophenolate mofetil—systemic scleroderma	7.17e-05	0.000685	CcSEcCtD
Irinotecan—Decreased appetite—Lisinopril—systemic scleroderma	7.16e-05	0.000684	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Lisinopril—systemic scleroderma	7.11e-05	0.000679	CcSEcCtD
Irinotecan—Fatigue—Lisinopril—systemic scleroderma	7.1e-05	0.000679	CcSEcCtD
Irinotecan—Shock—Mycophenolate mofetil—systemic scleroderma	7.1e-05	0.000678	CcSEcCtD
Irinotecan—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	7.07e-05	0.000676	CcSEcCtD
Irinotecan—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	7.06e-05	0.000675	CcSEcCtD
Irinotecan—Hypersensitivity—Leflunomide—systemic scleroderma	7.06e-05	0.000675	CcSEcCtD
Irinotecan—Pancreatitis—Methotrexate—systemic scleroderma	7.05e-05	0.000674	CcSEcCtD
Irinotecan—Constipation—Lisinopril—systemic scleroderma	7.04e-05	0.000673	CcSEcCtD
Irinotecan—Pain—Lisinopril—systemic scleroderma	7.04e-05	0.000673	CcSEcCtD
Irinotecan—Bradycardia—Prednisone—systemic scleroderma	7.01e-05	0.00067	CcSEcCtD
Irinotecan—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	6.97e-05	0.000667	CcSEcCtD
Irinotecan—Diarrhoea—Azathioprine—systemic scleroderma	6.94e-05	0.000664	CcSEcCtD
Irinotecan—Haemoglobin—Prednisone—systemic scleroderma	6.92e-05	0.000661	CcSEcCtD
Irinotecan—Nausea—Captopril—systemic scleroderma	6.91e-05	0.00066	CcSEcCtD
Irinotecan—Haemorrhage—Prednisone—systemic scleroderma	6.88e-05	0.000658	CcSEcCtD
Irinotecan—Anorexia—Mycophenolate mofetil—systemic scleroderma	6.88e-05	0.000657	CcSEcCtD
Irinotecan—Asthenia—Leflunomide—systemic scleroderma	6.87e-05	0.000657	CcSEcCtD
Irinotecan—Feeling abnormal—Lisinopril—systemic scleroderma	6.78e-05	0.000649	CcSEcCtD
Irinotecan—Connective tissue disorder—Prednisone—systemic scleroderma	6.76e-05	0.000647	CcSEcCtD
Irinotecan—Hypotension—Mycophenolate mofetil—systemic scleroderma	6.74e-05	0.000644	CcSEcCtD
Irinotecan—Gastrointestinal pain—Lisinopril—systemic scleroderma	6.73e-05	0.000644	CcSEcCtD
Irinotecan—Neutropenia—Methotrexate—systemic scleroderma	6.72e-05	0.000642	CcSEcCtD
Irinotecan—Dizziness—Azathioprine—systemic scleroderma	6.71e-05	0.000641	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Methotrexate—systemic scleroderma	6.68e-05	0.000638	CcSEcCtD
Irinotecan—Asthenia—Mycophenolic acid—systemic scleroderma	6.56e-05	0.000627	CcSEcCtD
Irinotecan—Diarrhoea—Leflunomide—systemic scleroderma	6.56e-05	0.000627	CcSEcCtD
Irinotecan—Insomnia—Mycophenolate mofetil—systemic scleroderma	6.52e-05	0.000624	CcSEcCtD
Irinotecan—Body temperature increased—Lisinopril—systemic scleroderma	6.51e-05	0.000622	CcSEcCtD
Irinotecan—Abdominal pain—Lisinopril—systemic scleroderma	6.51e-05	0.000622	CcSEcCtD
Irinotecan—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	6.48e-05	0.000619	CcSEcCtD
Irinotecan—Vomiting—Azathioprine—systemic scleroderma	6.45e-05	0.000617	CcSEcCtD
Irinotecan—Pneumonia—Methotrexate—systemic scleroderma	6.44e-05	0.000616	CcSEcCtD
Irinotecan—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	6.43e-05	0.000615	CcSEcCtD
Irinotecan—Somnolence—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000613	CcSEcCtD
Irinotecan—Rash—Azathioprine—systemic scleroderma	6.4e-05	0.000612	CcSEcCtD
Irinotecan—Dermatitis—Azathioprine—systemic scleroderma	6.39e-05	0.000611	CcSEcCtD
Irinotecan—Flushing—Prednisone—systemic scleroderma	6.39e-05	0.000611	CcSEcCtD
Irinotecan—Headache—Azathioprine—systemic scleroderma	6.36e-05	0.000608	CcSEcCtD
Irinotecan—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	6.35e-05	0.000607	CcSEcCtD
Irinotecan—Dizziness—Leflunomide—systemic scleroderma	6.34e-05	0.000606	CcSEcCtD
Irinotecan—Renal failure—Methotrexate—systemic scleroderma	6.3e-05	0.000602	CcSEcCtD
Irinotecan—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	6.27e-05	0.000599	CcSEcCtD
Irinotecan—Diarrhoea—Mycophenolic acid—systemic scleroderma	6.25e-05	0.000598	CcSEcCtD
Irinotecan—Stomatitis—Methotrexate—systemic scleroderma	6.25e-05	0.000597	CcSEcCtD
Irinotecan—Angiopathy—Prednisone—systemic scleroderma	6.24e-05	0.000597	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	6.23e-05	0.000595	CcSEcCtD
Irinotecan—Immune system disorder—Prednisone—systemic scleroderma	6.22e-05	0.000594	CcSEcCtD
Irinotecan—Constipation—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.00059	CcSEcCtD
Irinotecan—Pain—Mycophenolate mofetil—systemic scleroderma	6.17e-05	0.00059	CcSEcCtD
Irinotecan—Arrhythmia—Prednisone—systemic scleroderma	6.15e-05	0.000588	CcSEcCtD
Irinotecan—ABCB1—digestive system—systemic scleroderma	6.15e-05	0.00755	CbGeAlD
Irinotecan—Sweating—Methotrexate—systemic scleroderma	6.14e-05	0.000587	CcSEcCtD
Irinotecan—Vomiting—Leflunomide—systemic scleroderma	6.09e-05	0.000582	CcSEcCtD
Irinotecan—Alopecia—Prednisone—systemic scleroderma	6.08e-05	0.000581	CcSEcCtD
Irinotecan—Hypersensitivity—Lisinopril—systemic scleroderma	6.07e-05	0.00058	CcSEcCtD
Irinotecan—Dizziness—Mycophenolic acid—systemic scleroderma	6.04e-05	0.000578	CcSEcCtD
Irinotecan—Rash—Leflunomide—systemic scleroderma	6.04e-05	0.000578	CcSEcCtD
Irinotecan—Dermatitis—Leflunomide—systemic scleroderma	6.04e-05	0.000577	CcSEcCtD
Irinotecan—Nausea—Azathioprine—systemic scleroderma	6.03e-05	0.000576	CcSEcCtD
Irinotecan—Headache—Leflunomide—systemic scleroderma	6e-05	0.000574	CcSEcCtD
Irinotecan—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	5.94e-05	0.000568	CcSEcCtD
Irinotecan—Asthenia—Lisinopril—systemic scleroderma	5.91e-05	0.000565	CcSEcCtD
Irinotecan—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	5.9e-05	0.000564	CcSEcCtD
Irinotecan—Vomiting—Mycophenolic acid—systemic scleroderma	5.81e-05	0.000556	CcSEcCtD
Irinotecan—Haemoglobin—Methotrexate—systemic scleroderma	5.78e-05	0.000553	CcSEcCtD
Irinotecan—Rash—Mycophenolic acid—systemic scleroderma	5.76e-05	0.000551	CcSEcCtD
Irinotecan—Dermatitis—Mycophenolic acid—systemic scleroderma	5.76e-05	0.00055	CcSEcCtD
Irinotecan—Haemorrhage—Methotrexate—systemic scleroderma	5.75e-05	0.00055	CcSEcCtD
Irinotecan—Headache—Mycophenolic acid—systemic scleroderma	5.73e-05	0.000547	CcSEcCtD
Irinotecan—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	5.7e-05	0.000545	CcSEcCtD
Irinotecan—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	5.7e-05	0.000545	CcSEcCtD
Irinotecan—Nausea—Leflunomide—systemic scleroderma	5.69e-05	0.000544	CcSEcCtD
Irinotecan—Diarrhoea—Lisinopril—systemic scleroderma	5.63e-05	0.000539	CcSEcCtD
Irinotecan—Ill-defined disorder—Prednisone—systemic scleroderma	5.56e-05	0.000531	CcSEcCtD
Irinotecan—Visual impairment—Methotrexate—systemic scleroderma	5.54e-05	0.00053	CcSEcCtD
Irinotecan—Anaemia—Prednisone—systemic scleroderma	5.54e-05	0.000529	CcSEcCtD
Irinotecan—Dizziness—Lisinopril—systemic scleroderma	5.44e-05	0.00052	CcSEcCtD
Irinotecan—Nausea—Mycophenolic acid—systemic scleroderma	5.43e-05	0.000519	CcSEcCtD
Irinotecan—Malaise—Prednisone—systemic scleroderma	5.4e-05	0.000516	CcSEcCtD
Irinotecan—Vertigo—Prednisone—systemic scleroderma	5.38e-05	0.000515	CcSEcCtD
Irinotecan—Syncope—Prednisone—systemic scleroderma	5.37e-05	0.000514	CcSEcCtD
Irinotecan—Cardiac disorder—Methotrexate—systemic scleroderma	5.34e-05	0.00051	CcSEcCtD
Irinotecan—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	5.31e-05	0.000508	CcSEcCtD
Irinotecan—Loss of consciousness—Prednisone—systemic scleroderma	5.27e-05	0.000503	CcSEcCtD
Irinotecan—Vomiting—Lisinopril—systemic scleroderma	5.23e-05	0.0005	CcSEcCtD
Irinotecan—Angiopathy—Methotrexate—systemic scleroderma	5.22e-05	0.000499	CcSEcCtD
Irinotecan—Immune system disorder—Methotrexate—systemic scleroderma	5.2e-05	0.000497	CcSEcCtD
Irinotecan—Rash—Lisinopril—systemic scleroderma	5.19e-05	0.000496	CcSEcCtD
Irinotecan—Dermatitis—Lisinopril—systemic scleroderma	5.19e-05	0.000496	CcSEcCtD
Irinotecan—Mediastinal disorder—Methotrexate—systemic scleroderma	5.18e-05	0.000496	CcSEcCtD
Irinotecan—Asthenia—Mycophenolate mofetil—systemic scleroderma	5.18e-05	0.000495	CcSEcCtD
Irinotecan—Hypertension—Prednisone—systemic scleroderma	5.17e-05	0.000494	CcSEcCtD
Irinotecan—Chills—Methotrexate—systemic scleroderma	5.16e-05	0.000493	CcSEcCtD
Irinotecan—Headache—Lisinopril—systemic scleroderma	5.16e-05	0.000493	CcSEcCtD
Irinotecan—ABCB1—lung—systemic scleroderma	5.13e-05	0.00631	CbGeAlD
Irinotecan—Alopecia—Methotrexate—systemic scleroderma	5.08e-05	0.000486	CcSEcCtD
Irinotecan—Discomfort—Prednisone—systemic scleroderma	5.04e-05	0.000482	CcSEcCtD
Irinotecan—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	4.94e-05	0.000472	CcSEcCtD
Irinotecan—Nausea—Lisinopril—systemic scleroderma	4.89e-05	0.000467	CcSEcCtD
Irinotecan—Anaphylactic shock—Prednisone—systemic scleroderma	4.89e-05	0.000467	CcSEcCtD
Irinotecan—Oedema—Prednisone—systemic scleroderma	4.89e-05	0.000467	CcSEcCtD
Irinotecan—Infection—Prednisone—systemic scleroderma	4.86e-05	0.000464	CcSEcCtD
Irinotecan—Back pain—Methotrexate—systemic scleroderma	4.84e-05	0.000463	CcSEcCtD
Irinotecan—Shock—Prednisone—systemic scleroderma	4.81e-05	0.00046	CcSEcCtD
Irinotecan—Nervous system disorder—Prednisone—systemic scleroderma	4.8e-05	0.000458	CcSEcCtD
Irinotecan—Dizziness—Mycophenolate mofetil—systemic scleroderma	4.77e-05	0.000456	CcSEcCtD
Irinotecan—Hyperhidrosis—Prednisone—systemic scleroderma	4.73e-05	0.000452	CcSEcCtD
Irinotecan—Anorexia—Prednisone—systemic scleroderma	4.66e-05	0.000446	CcSEcCtD
Irinotecan—Ill-defined disorder—Methotrexate—systemic scleroderma	4.65e-05	0.000444	CcSEcCtD
Irinotecan—Anaemia—Methotrexate—systemic scleroderma	4.63e-05	0.000442	CcSEcCtD
Irinotecan—Vomiting—Mycophenolate mofetil—systemic scleroderma	4.59e-05	0.000438	CcSEcCtD
Irinotecan—Rash—Mycophenolate mofetil—systemic scleroderma	4.55e-05	0.000435	CcSEcCtD
Irinotecan—Dermatitis—Mycophenolate mofetil—systemic scleroderma	4.54e-05	0.000434	CcSEcCtD
Irinotecan—Headache—Mycophenolate mofetil—systemic scleroderma	4.52e-05	0.000432	CcSEcCtD
Irinotecan—Malaise—Methotrexate—systemic scleroderma	4.52e-05	0.000432	CcSEcCtD
Irinotecan—Vertigo—Methotrexate—systemic scleroderma	4.5e-05	0.00043	CcSEcCtD
Irinotecan—Leukopenia—Methotrexate—systemic scleroderma	4.48e-05	0.000428	CcSEcCtD
Irinotecan—Insomnia—Prednisone—systemic scleroderma	4.42e-05	0.000423	CcSEcCtD
Irinotecan—Paraesthesia—Prednisone—systemic scleroderma	4.39e-05	0.00042	CcSEcCtD
Irinotecan—Cough—Methotrexate—systemic scleroderma	4.37e-05	0.000418	CcSEcCtD
Irinotecan—Dyspepsia—Prednisone—systemic scleroderma	4.3e-05	0.000411	CcSEcCtD
Irinotecan—Nausea—Mycophenolate mofetil—systemic scleroderma	4.28e-05	0.00041	CcSEcCtD
Irinotecan—Decreased appetite—Prednisone—systemic scleroderma	4.25e-05	0.000406	CcSEcCtD
Irinotecan—Fatigue—Prednisone—systemic scleroderma	4.22e-05	0.000403	CcSEcCtD
Irinotecan—Discomfort—Methotrexate—systemic scleroderma	4.21e-05	0.000403	CcSEcCtD
Irinotecan—Constipation—Prednisone—systemic scleroderma	4.18e-05	0.0004	CcSEcCtD
Irinotecan—Confusional state—Methotrexate—systemic scleroderma	4.12e-05	0.000394	CcSEcCtD
Irinotecan—Anaphylactic shock—Methotrexate—systemic scleroderma	4.09e-05	0.000391	CcSEcCtD
Irinotecan—Infection—Methotrexate—systemic scleroderma	4.06e-05	0.000388	CcSEcCtD
Irinotecan—Feeling abnormal—Prednisone—systemic scleroderma	4.03e-05	0.000385	CcSEcCtD
Irinotecan—Nervous system disorder—Methotrexate—systemic scleroderma	4.01e-05	0.000383	CcSEcCtD
Irinotecan—Thrombocytopenia—Methotrexate—systemic scleroderma	4e-05	0.000382	CcSEcCtD
Irinotecan—Gastrointestinal pain—Prednisone—systemic scleroderma	4e-05	0.000382	CcSEcCtD
Irinotecan—Hyperhidrosis—Methotrexate—systemic scleroderma	3.95e-05	0.000378	CcSEcCtD
Irinotecan—Anorexia—Methotrexate—systemic scleroderma	3.9e-05	0.000372	CcSEcCtD
Irinotecan—Abdominal pain—Prednisone—systemic scleroderma	3.87e-05	0.00037	CcSEcCtD
Irinotecan—Body temperature increased—Prednisone—systemic scleroderma	3.87e-05	0.00037	CcSEcCtD
Irinotecan—Hypotension—Methotrexate—systemic scleroderma	3.82e-05	0.000365	CcSEcCtD
Irinotecan—Insomnia—Methotrexate—systemic scleroderma	3.7e-05	0.000353	CcSEcCtD
Irinotecan—Paraesthesia—Methotrexate—systemic scleroderma	3.67e-05	0.000351	CcSEcCtD
Irinotecan—Dyspnoea—Methotrexate—systemic scleroderma	3.64e-05	0.000348	CcSEcCtD
Irinotecan—Somnolence—Methotrexate—systemic scleroderma	3.63e-05	0.000347	CcSEcCtD
Irinotecan—Hypersensitivity—Prednisone—systemic scleroderma	3.6e-05	0.000344	CcSEcCtD
Irinotecan—Dyspepsia—Methotrexate—systemic scleroderma	3.6e-05	0.000344	CcSEcCtD
Irinotecan—Decreased appetite—Methotrexate—systemic scleroderma	3.55e-05	0.00034	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Methotrexate—systemic scleroderma	3.53e-05	0.000337	CcSEcCtD
Irinotecan—Fatigue—Methotrexate—systemic scleroderma	3.52e-05	0.000337	CcSEcCtD
Irinotecan—Asthenia—Prednisone—systemic scleroderma	3.51e-05	0.000335	CcSEcCtD
Irinotecan—Pain—Methotrexate—systemic scleroderma	3.49e-05	0.000334	CcSEcCtD
Irinotecan—Feeling abnormal—Methotrexate—systemic scleroderma	3.37e-05	0.000322	CcSEcCtD
Irinotecan—Diarrhoea—Prednisone—systemic scleroderma	3.35e-05	0.00032	CcSEcCtD
Irinotecan—Gastrointestinal pain—Methotrexate—systemic scleroderma	3.34e-05	0.000319	CcSEcCtD
Irinotecan—Dizziness—Prednisone—systemic scleroderma	3.23e-05	0.000309	CcSEcCtD
Irinotecan—Abdominal pain—Methotrexate—systemic scleroderma	3.23e-05	0.000309	CcSEcCtD
Irinotecan—Body temperature increased—Methotrexate—systemic scleroderma	3.23e-05	0.000309	CcSEcCtD
Irinotecan—Vomiting—Prednisone—systemic scleroderma	3.11e-05	0.000297	CcSEcCtD
Irinotecan—Rash—Prednisone—systemic scleroderma	3.08e-05	0.000295	CcSEcCtD
Irinotecan—Dermatitis—Prednisone—systemic scleroderma	3.08e-05	0.000294	CcSEcCtD
Irinotecan—Headache—Prednisone—systemic scleroderma	3.06e-05	0.000293	CcSEcCtD
Irinotecan—Hypersensitivity—Methotrexate—systemic scleroderma	3.01e-05	0.000288	CcSEcCtD
Irinotecan—Asthenia—Methotrexate—systemic scleroderma	2.93e-05	0.00028	CcSEcCtD
Irinotecan—Nausea—Prednisone—systemic scleroderma	2.9e-05	0.000278	CcSEcCtD
Irinotecan—Diarrhoea—Methotrexate—systemic scleroderma	2.8e-05	0.000267	CcSEcCtD
Irinotecan—Dizziness—Methotrexate—systemic scleroderma	2.7e-05	0.000258	CcSEcCtD
Irinotecan—Vomiting—Methotrexate—systemic scleroderma	2.6e-05	0.000248	CcSEcCtD
Irinotecan—Rash—Methotrexate—systemic scleroderma	2.58e-05	0.000246	CcSEcCtD
Irinotecan—Dermatitis—Methotrexate—systemic scleroderma	2.57e-05	0.000246	CcSEcCtD
Irinotecan—Headache—Methotrexate—systemic scleroderma	2.56e-05	0.000245	CcSEcCtD
Irinotecan—Nausea—Methotrexate—systemic scleroderma	2.43e-05	0.000232	CcSEcCtD
